# New Predictive Marker for Pancreatic Cancer Using CA19-9 and Fecal Elastase

> **NCT05923567** · — · UNKNOWN · sponsor: **Gangnam Severance Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Paancreatic Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05923567
- **Lead sponsor:** Gangnam Severance Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-18
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05923567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05923567, "New Predictive Marker for Pancreatic Cancer Using CA19-9 and Fecal Elastase". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05923567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*